Concordance of Management Recommendations by Expert Panel Based on Evaluation of Bone Lesions on BS Plus ceCT or 18F-FDG PET Plus ceCT
| Recommendation | 18F-FDG PET plus ceCT | BS plus ceCT | Concordant recommendation |
| Treatment intent | |||
| Curative | 7 (6.9) | 11 (10.8) | 5 (4.9) |
| Noncurative | 83 (81.4) | 77 (75.5) | 76 (74.5) |
| Unable to determine | 3 (2.9) | 5 (4.9) | 1 (1.1) |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
| Systemic therapy | |||
| None | 0 | 2 (2.0) | 0 |
| Antihormonal | 57 (55.9) | 53 (52.0) | 51 (50) |
| Chemotherapy | 14 (13.7) | 10 (9.8) | 10 (9.8) |
| Chemotherapy plus targeted therapy | 17 (16.7) | 16 (15.7) | 16 (15.7) |
| Unable to determine | 5 (4.9) | 12 (11.8) | 3 (2.9) |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
| CAD/bisphosphonate | |||
| No | 15 (14.7) | 27 (26.5) | 14 (13.7) |
| Yes | 77 (75.5) | 62 (60.8) | 62 (60.8) |
| Unable to determine | 1 (1.0) | 4 (3.9) | 0 |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
| Radiotherapy | |||
| None | 62 (60.8) | 56 (60.2) | 39 (38.2) |
| Curative | 10 (9.8) | 6 (6.5) | 2 (2.0) |
| Noncurative | 20 (19.6) | 25 (26.9) | 8 (7.8) |
| Unable to determine | 1 (1.0) | 6 (6.5) | 1 (1.0) |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
| Radiography/MRI | |||
| No | 63 (61.8) | 65 (63.7) | 53 (52.0) |
| Yes | 30 (29.4) | 28 (27.5) | 18 (17.6) |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
| Other imaging† | |||
| No | 92 (90.2) | 66 (64.7) | 39 (38.2) |
| Yes | 1 (1.0) | 27 (26.5) | 1 (1.0) |
| Not evaluated* | 9 (8.8) | 9 (8.8) | 9 (8.8) |
↵* For patients without bone lesions on any imaging modalities, it was assumed that management recommendations would be concordant between scenarios with 18F-FDG PET plus ceCT and BS plus ceCT and that there would be no requests for additional imaging to evaluate bone lesions, without evaluation of expert panel.
↵† Additional 18F-FDG PET in case of available BS and vice versa.
CAD = calcium, vitamin D.
Data are numbers followed by percentages in parentheses. n = 102 patients.